Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

NCT00083707 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Thalidomide

Sponsor

University of Arkansas

Collaborators

[object Object]